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able that for subjects showing severe symptoms, the quality of life and the sleep 
is also improved.
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COMPARATIVE ASSESSMENT Of HEAlTH IMPACT Of PREVENTION fOR 9 
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Hung M.C.1, Lai W.W.2, Hwang J.S.3, Wang J.D.4
1Department of Public Health, National Cheng Kung University Medical College, Tainan, Taiwan, 
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Objectives: We conducted this study to estimate the saving of loss-of-QALE 
(quality-adjusted life expectancy) for 9 different cancers and validated them with 
estimation of EYLL (expected years of life loss) plus expected years of living with 
disability (EYLD). MethOds: 395,330 patients with pathologically verified can-
cer registered in the National Cancer Registry in Taiwan between 1998 and 2007 
were used to estimate the survival functions and extrapolate to lifetime through 
a semi-parametric method. EYLL for cancer was calculated by subtracting the life 
expectancy of the cancer cohort from that of the age-and sex-matched general 
population. A convenience sample of 6,189 measurements of EQ-5D was collected 
for utility values and proportions of functional disability to estimate their QALE and 
EYLD. The loss of QALE for these patients was calculated by assuming a uniform 
utility of one for the age- and gender- matched reference subjects simulated from 
the hazard functions of vital statistics, and subtracting the QALE of these cancer 
cohorts. We also estimated the lifetime risks for different cancers with Cumulative 
incidence rates (CIR20-79) and multiplied with loss-of-QALE to obtain the expected 
impact. Results: EYLL plus EYLD were similar to loss-of-QALE. Male patients with 
esophageal cancer suffered the highest loss-of-QALE of 18.37 QALY (quality-adjusted 
life year), equivalent to 18.19 years of EYLL plus EYLD; those of female patients with 
lung cancer were 16.57 QALY and 17.1 years, respectively. After multiplied with 
the lifetime risk, liver cancer in male and breast cancer in female were expected 
to have the highest impact, or loss of 1.10-1.11 and 0.58-0.65 QALY or life-years, 
respectively. cOnclusiOns: Estimated EYLL plus EYLD are close to loss-of-QALE 
and both can be used for measuring impact of cancer prevention. Simultaneous 
consideration of lifetime risk would provide a more accurate estimate for compara-
tive risk assessment.
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EVIDENCE-bASED PRESCRIbINg: USINg ExISTINg DATA ON bENEfITS AND 
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1London School of Economics, London, UK, 2University of Groningen, Groningen, The Netherlands, 
3University of Bristol, Bristol, UK, 4Patient-Centered Outcomes Research Institute (PCORI), 
Washington, DC, USA
Objectives: Even in cases where comparative clinical data exist, decision-makers 
often struggle to weigh the relative benefits and harms of multiple drugs. We pre-
sent the potential benefit of combining network meta-analysis (NMA) with multi-
criteria decision analysis (MCDA) in order to formalize the incorporation of clinical 
evidence and qualitative preferences into prescribing decisions. MethOds: Using a 
systematic review and NMA of cholesterol-lowering statins as a case study, we com-
pared the absolute risk of mortality, coronary and cerebrovascular events, myalgia, 
creatine kinase and transaminase elevations, and discontinuations due to adverse 
events associated with atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvas-
tatin, and simvastatin. We applied a structured benefit-risk model that allowed 
evidence on multiple outcomes to be combined using qualitative preferences, 
assuming that the effect of statins on preventing mortality was more important 
than either major coronary or cerebrovascular events, which were in turn more 
important than any one of the harm outcomes. Results: There were 184 ran-
domized controlled trials of statins including 260,630 individuals. Our previous 
NMA found statistically detectable differences among individual statins in terms of 
both benefit and harm outcomes. When all outcomes were combined using MCDA, 
fluvastatin had a considerable probability of both being the best (41%) and worst 
(12%) statin, reflecting the uncertainty in its evidence base. In contrast, simvastatin 
had a high probability of better ranks (36%) with a negligible probability of ranking 
worst (~1%). cOnclusiOns: Clinical evidence can be combined with qualitative 
preferences at point-of-care settings when making prescribing decisions. The com-
bination of NMA with MCDA holds the promise to introduce more transparency to 
the decision-making process and potentially increase the relevance and informative 
value of existing evidence for prescribing decisions. Adopting such an approach for 
cholesterol-lowering therapy suggests that simvastatin may potentially have the 
most favorable benefit-harm profile among statins.
PRM3
A COMPARISON Of 3 ASSESSMENTS IN THE TREATMENT Of ROSACEA IN THE 
CONTExT Of A COMPARATIVE EffECTIVENESS STUDy
Kendall J., Winkelman W.
Galderma Laboratories, L.P., Fort Worth, T.X.
Objectives: A comparative crossover study was conducted to assess the efficacy 
of brimonidine gel 0.33% (BG) vs azelaic acid gel 15% (AG) for the treatment of per-
sistent facial erythema of rosacea using three assessments: clinician’s erythema 
assessment (CEA), patient self-assessment (PSA), and chromameter instrumenta-
tion. MethOds: This was a multicenter, randomized, controlled, double-masked 
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Objectives: The objectives of this study were to describe the COPD population 
and treatment patterns, to estimate treatment adherence, and to compare medi-
cation cost, in a real life setting, using the Régie de l’assurance maladie du Québec 
(RAMQ) database. MethOds: Patients who had a diagnosis of COPD (ICD-9 codes: 
4910-4929, 4960-4969), or who received at least one script of a COPD medication 
from January 1st 2010 to January 31st 2013 were selected. Patient’s characteristics, 
drug utilization patterns, adherence, and costs were analyzed. Results: Among 
patients with a COPD diagnosis, 3,015 patients were treated with LABA (long-acting 
beta-agonists); 12,099 with LAAC (long-acting anticholinergics); and 11,029 with 
a fixed-combination of LABA/inhaled corticosteroids (ICS). A proportion of 26.1%, 
23.6%, and 31.0% of LABA, LAAC, and LABA/ICS users, respectively, had a mixed 
diagnosis with asthma. More than 80% of patients on long-acting agent treat-
ments used more than one medication in concomitance. The results showed a 
high usage of ICS in concomitance with LAAC (20.3% in free-combination; 53.2% 
in fixed-combination). In incident users (no COPD medication in the previous year) 
treated with triple therapy LAAC+LABA/ICS (n= 125), average time to triple therapy 
was less than six months. The compliance, estimated over up to 1-year period, of 
long-acting COPD medications given more than once daily was 41.4%. The switch 
to once-daily medication was associated with a compliance of 61.4%. The com-
pliance of the medications used before the switch to once-daily medication was 
30.5%. The persistence of long-acting COPD medications given more than once 
daily was 72.3% at 6 months. At 6 months, the persistence of once-daily medication 
was 76.7%. The mean monthly cost per medication was CDN$46.65 (SD= 39.21) for 
LABA users, CDN$63.14 (SD= 121.79) for LAAC users, and CDN$96.20 (SD= 162.43) 
for LABA/ICS users. cOnclusiOns: Medication given once daily was associated 
with a higher level of treatment compliance.
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IMMUNOTHERAPy IN A gEOPARDIzED REIMbURSEMENT SITUATION: THE 
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Objectives: Allergic rhinoconjuntivitis is a global health problem, and many 
studies have shown an important increase in the disease prevalence in the last 
20 years. Allergen specific immunotherapy (SIT) is the only available treatment 
for the underlying cause of the disease. At present, few economic evaluations are 
available for Italy. The present study is focused on the cost effectiveness of SIT in 
Italy, considering the fragmented reimbursement policies in different Regions of 
the Country. MethOds: A review of the literature on the pharmaco-economy of 
immunotherapy for allergic rhinoconjuntivitis with a special focus on Italy (costs 
taken from Italian formularies, tariffs and Diagnosis Related Groups, or DRG). 
Reimbursement values were taken from official regional resolutions Results: 
Treatment with SIT reduced by 38% symptomatic drugs consumption (whose costs 
are ranging from € 0.1 to € 0.5 per unit). Moreover, SIT reduced by 30% symptoms 
intensity (impacting on GPs and specialists visits, whose cost are ranging from € 13 
to € 18, respectively) and by 20% the development of allergic asthma (which implies € 
190 for one day of hospitalization). There are wide differences in SIT reimbursement 
across Italian Regions, ranging from 100% in 3, to various level of copayment in 7, 
down to no reimbursement in 10. cOnclusiOns: Overall, these data support the 
favorable impact of SIT on the medium-long term in front of a relative cost increase 
in the short term. This benefit is still not fully recognized in Italy where differences 
persist across regions in the access to SIT reimbursement.
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IMPACT, IN REAl lIfE CONDITIONS, Of THE USE Of A PURIfIER SPRAy ON 
AllERgy CARE IN DUST MITE AllERgIC SUbjECTS
Taieb C.1, Ripoll C.2
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Objectives: The study has been set-up in order to evaluate in real life conditions 
the perceived efficacy of a spray containing essential oils on allergy-related-symp-
toms, day-sleepiness and QoL of allergic subjects. MethOds: Women-and-men 
with a known history of dust mite allergy were recruited in the study. They were 
asked to use in their house twice a day, the purifier spray for a period of 28days. 
The perceived efficacy was evaluated via self-validated questionnaires on allergy 
symptoms (discomfort generated by sneezing- itchy eyes-stuffy nose-nasal flow-
tiredness-ear itching), on daytime-sleepiness (Epworth-Sleepiness-Scale) and on 
QoL (SF12). For the study outcomes, each subject was evaluated at inclusion, at 
day7 and day28. The satisfaction through the CSQ8-questionnaire was also evalu-
ated at day28. Results: 42 subjects, with an history of allergy of 21.4±11.2years, 
were included. They present a symptom-score at inclusion of 6.63±3.5 which was 
significantly reduced after 7 days of spray use with a value of 3.87±2.4 (p< 0,0001). 
The improvement was confirmed at day28:1.85±1.6-(p< 0,0001). The data were also 
evaluated according to symptom severity, i.e.low, moderate or severe. For the mod-
erate or severe subpopulations, a significant improvement was observed on the 
symptoms score since 7days of spray use. Moreover, for the subjects showing severe 
symptoms, an improvement was also observed on daytime-sleepiness (p< 0,05) with 
the Epworth score going from 9.18 ±7.1 to 4.75 ±3.9 after 28days, and on the SF12 
mental dimension score (42.8 vs 48.2-p< 0,04) For the studied population the over-
all satisfaction evaluated was above 75% after 28days. cOnclusiOns: By using 
self-validated-questionnaires, the evaluation shows the interest of the use of the 
essential oils spray in allergy care for dust mite allergic subjects. The improvement 
on symptoms is observed whatever the severity of symptoms is, and it is notice-
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the recovery of patients after discharge from hospital following total knee arthro-
plasty (TKA). This systematic literature review aims to evaluate the effectiveness 
of home telerehabilitation in patients who underwent TKA. MethOds: Studies 
published in the English language between 2000 and 2014 were retrieved from 
Embase, PubMed and Cochrane databases using relevant search strategies. Two 
researchers independently reviewed studies as per the Cochrane methodology for 
systematic reviews. We considered telerehabilitation sessions as those that were 
conducted using videoconferencing by experienced physiotherapists to patients’ 
home via an internet connection. The outcomes assessed include knee movement 
(knee extension and flexion); quadriceps muscle strength; functional assessment 
(the timed up-and-go test); assessment of pain, stiffness and functional capacity 
with Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 
and visual analog scale (VAS) for pain. Results: In total, 160 potentially relevant 
studies were screened. Following screening of studies as abstracts and full-text 
publications, seven primary publications (four randomized controlled trials [RCT], 
one non-RCT, and two single arm trials) were included in the review. Patients 
experienced high levels of satisfaction with the use of telerehabilitation alone. The 
patients in the home telerehabilitation group showed improvement in physical 
activity and functional status similar to patients in conventional therapy group 
(comparative studies). The detailed analyses of the findings from studies are still 
ongoing and will be presented on completion. cOnclusiOns: A preliminary 
analysis shows that home telerehabilitation method is an acceptable rehabilita-
tion method to patients who underwent TKA. The evidence from this systematic 
literature review will hopefully demonstrate telerehabilitation to be a practical 
alternative to conventional face-to-face rehabilitation therapy in patients who 
underwent TKA.
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RECURRENCE Of EPISODES Of HEPATIC ENCEPHAlOPATHy
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Objectives: Hepatic encephalopathy (HE) is a serious complication of liver disease. 
HE presents as a spectrum of neurocognitive impairments, from mild HE to coma. 
Direct measurement, or derivation of utility values related to treatment using a 
generic QoL mapping procedure may not provide the most valid measures, given 
the nature of the condition. Rifaximin-α is a treatment for HE that has been shown 
to reduce the recurrence of HE and HE-related hospitalisation. Following an exer-
cise using a disease specific instrument that yielded a utility difference of 0.155 
units, here we attempted to indirectly estimate the utility impact of Rifaximin-α in 
patients with HE. MethOds: Data from a six month, phase-3 RCT of rifaximin-α 
in HE patients was used. In this study, monthly PROs including SF-36 were recorded 
until an HE event had occurred or until the end of study. We estimated the EQ-5D 
index (estEQ-5Dindex) using a recognised SF-12 mapping procedure. Due to missing 
observations and differences in baseline utility, linear interpolation of utility values 
was applied, and the individual changes from baseline in the estEQ-5Dindex were 
characterised. Results: At baseline, the estEQ-5Dindex was 0.563 units (SD 0.263) 
units in the rifaximin-α arm, and 0.587 (0.211) in the placebo arm (p= 0.368). There 
was no discernible difference using mean values throughout (overall mean estEQ-
5Dindex at end of study 0.643 (0.23) for rifaximin-α vs. 0.647 (0.24; p= 0.922)). The 
overall percentage of missing data was 20% of subjects and 14% of potential observa-
tions. The mean difference from end of study to baseline in utility was 0.018 units 
(SEM 0.02 for rifaximin-α vs. -0.013 for placebo (0.031; p= 0.171). cOnclusiOns: 
Even with an insensitive methodology using generic quality of life we demonstrated 
that rifaximin-α was associated with a discernible, clinically meaningful change in 
utility in cognitively impaired patients. In these patients, direct measurement of 
utility using a PRO was inappropriate.
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THE IMPlEMENTATION Of THE ExTRACT Of CENTARIA ISlANDICA IN 
PATIENTS SUffERINg fROM EgzACERbATION Of CHRONIC PHARyNgITIS
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Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia and Montenegro
Objectives: The objective of this paper is to establish if the implementation of 
Isla lozenges influences the intensity of sore throat sensation in patients suf-
fering from egzacerbation of chronic pharyngitis and whether their use influ-
ences the need of antibiotic therapy administration. MethOds: The number of 
60 patients with egzacerbation of chronic pharyngitis has been observed. 30 of 
them used Isla lozenges during 10 days/ 6 times a day, while the remaining 30 
did not take any. According to the VAS scale (0-10 cm) the intensity of sore throat 
sensation was determined at the beginning of the disease and after 10 days. Also, 
it was determined in how many patients it was necessary to introduce antibi-
otic therapy. Results: The average value of sore throat sensation in the initial 
stage in the group in which Isla lozenges were administered was 6.80, while in 
the group that did not take them was 6.60; p> 0,05. After ten days of trial, the 
average value in the group that took Isla lozenges was 1.60; p< 0,05. In the group 
that did not take the lozenges, the average sore troat sensation was 5.90 after 
ten days; p> 0,05. The average values of sore troat sensation after 10 days of Isla 
lozenges implementation were statistically significantly lower in comparison to 
the second group; p< 0,05. The group in which Isla lozenges were given for 10 
days, 5 patients needed additional antibiotic therapy, whereas it was 14 patients 
in the second group; p< 0,05. cOnclusiOns: Implementation of Isla lozenges in 
patients with egzacerbation of chronic pharyngitis statistically significantly low-
ers the intensity of sore throat sensation as well as the need for later antibiotic 
therapy administration. This research was supported by Provincial Secretariat 
for Science and Technological Development, Autonomous Province of Vojvodina 
project No 114-451-3551/2013-01
crossover design study. Seventy men and women with moderate to severe erythema 
of rosacea were included. Subjects were randomized 1:1 to either BG once daily or 
AG twice daily for 15 days. After a washout period, subjects were given the other 
treatment for 15 days. The primary efficacy endpoint was composite success defined 
as a 2-grade improvement in both the CEA and PSA 6 hours after application on 
day 15. Secondary endpoints included 2-grade improvement in CEA and PSA and 
changes in chromameter readings 6 hours after application on day 15. All outcomes 
were in comparison to baseline (Day 0). Results: Per the protocol, the results of 
the second period were discarded as there was significant treatment carryover 
from the first period. The percentage of subjects with composite success in period 
1 was 14.3% and 5.7% for BG and AG, respectively. The percentage of subjects with 
a 2-grade improvement for CEA was 37.1% and 11.4% for BG and AG, respectively 
and those with a 2-grade improvement in PSA was 28.6% and 20.0% for BG and AG, 
respectively. Chromameter readings decreased by 9.64% and 2.38% for BG and AG, 
respectively. cOnclusiOns: Improvements were larger and more pronounced with 
the CEA and chromameter than with the PSA suggesting that subjects may view 
their rosacea severity and improvements with treatment differently than either a 
clinician or objective instrumentation.
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A SCOPINg lITERATURE REVIEW ON THE ExTERNAl VAlIDITy Of 
RANDOMIzED CONTROllED TRIAl POPUlATIONS
Curtis S.E.1, Kennedy-Martin T.2, Faries D.E.1, Robinson S.2, Johnston J.A.1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Kennedy Martin Health Outcomes, East Sussex, 
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Objectives: The aim of this scoping literature review was to report the findings of 
studies that have attempted to quantify external validity by comparing the patient 
population included in randomized controlled trials (RCTs) with patients from every-
day clinical practice. MethOds: We conducted a literature review of English language 
journal articles published since 2003 that compared a RCT patient population with a 
‘real-life’ patient population. Studies were limited to pharmaceutical interventions 
undertaken in adults. A protocol was developed that outlined the search approach. 
A range of databases were interrogated (MEDLINE; EMBASE; Science Citation Index; 
Cochrane Methodology Register). Double abstract review and data extraction were 
performed in line with protocol specifications. Results: Out of 5456 de-duplicated 
abstracts, there were 73 studies that met the inclusion criteria. Studies covered a 
range of therapy areas, with the majority undertaken in mental health (n= 18), cardi-
ology (n= 16), and oncology (n= 13). Studies either assessed the proportion of people 
from a clinical setting that would be eligible for an RCT or undertook a post-hoc 
analysis of RCT patient characteristics compared with the real-world population. A 
range of comparisons were made, including demographic, socioeconomic, and clini-
cal parameters. The vast majority of studies (n= 59) concluded that study selection 
criteria excluded many patients from clinical practice; most commented on how 
this limited the RCT’s external validity. A number of recommendations were made 
to improve the generalizability of RCTs or facilitate better understanding of their 
limitations. cOnclusiOns: RCTs designed to maximize internal validity frequently 
result in a loss of external validity. Designers of RCTs should carefully weigh inclusion/
exclusion criteria to ensure study objectives are met without unnecessarily sacrificing 
external validity, and the extent to which generalizability is compromised should be 
reported. Ultimately, a combination of explanatory and pragmatic studies is necessary 
to meet the diverse needs of regulators, prescribers, payers, and patients.
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Objectives: The lifetime functional disabilities associated with cancer have 
received little attention in the literature. This study determines the dynamic changes 
of different physical functional disabilities over time and their total duration after 
cancer diagnosis to understand their potential long-term care needs. MethOds: 
395,330 patients with pathologically verified cancer registered in the National 
Cancer Registry in Taiwan between 1998 and 2007were used to estimate the sur-
vival functions and extrapolate to lifetime through a semi-parametric method. A 
convenience sample of 6,189 measurements of patient’s functional disability with 
EQ-5D was collected for measuring impairment levels and care needs. Lifetime 
functional disabilities were obtained by extrapolating the gender and age-stratified 
survival functions to lifetime, and multiplying them with the proportions of differ-
ent kinds of functional disability over time. Results: The common care needs for 
cancer patients were mobility and usual activity; the older the patient, the higher 
the prevalence of functional disabilities and care needs; the shorter the life expec-
tancies (LE), the higher the proportion of expected years of living with disability 
(EYLD). Male patients with nasopharyngeal and oral cancer represented the longest 
for EYLD, or were 2.66 and 2.07 years, respectively, which would be about 20 and 
17 percent of their LE’s. The EYLD of cervical cancer was over 3.6 years, or about 9 
to 40 percent of their LE. cOnclusiOns: Cancer patients suffer from functional 
disabilities approximately 1.4 to 31.2 percent of their remaining lifetime, and may 
in need of long-term care. More detailed studies are warranted to comprehensively 
care these patients.
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ROlE Of TElEREHAbIlITATION IN PATIENTS fOllOWINg TOTAl kNEE 
ARTHROPlASTy: EVIDENCE fROM SySTEMATIC lITERATURE REVIEW
Shukla H., Nair S.R., Shaikh J.S., Thakker D., Sharma D.
Capita India Pvt. Ltd., Mumbai, India
Objectives: Increased physical activity and functional ability are the goals of 
total knee replacement surgery. Therefore, adequate rehabilitation is required for 
